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type 2A
Iciar Sánchez-Albisua1*, Saskia Frölich1, Peter G Barth2, Maja Steinlin3 and Ingeborg Krägeloh-Mann1Abstract
Introduction: Pontocerebellar hypoplasia Type 2 (PCH2) is a rare autosomal recessive condition, defined on MRI by
a small cerebellum and ventral pons. Clinical features are severe developmental delay, microcephaly and dyskinesia.
Ninety percent carry a p.A307S mutation in the TSEN54-gene. Our aim was to describe the natural course including
neurological and developmental features and other aspects of care in a homogeneous group of PCH2 patients all
carrying the p.A307S mutation.
Patients and methods: Patients were recruited via the German patients' organizations. Inclusion criteria were imaging
findings of PCH2 and a p.A307S mutation. Data were collected using medical reports and patient questionnaires
discussed in a standardized telephone interview.
Results: Thirty-three patients were included. When considering survival until age 11 years, 53% of children had
died Weight, length and head circumference, mostly in the normal range at birth, became abnormal, especially
head circumference (-5.58 SD at age 5 yrs). Neurologic symptoms: Choreathetosis was present in 88% (62% with
pyramidal signs), 12% had pure spasticity. Epileptic seizures were manifest in 82%, status epilepticus in 39%.
Non-epileptic dystonic attacks occurred in 33%. General symptoms: feeding difficulties were recorded in 100%,
sleep disorder in 96%, apneas in 67% and recurrent infections in 52%; gastroesophageal reflux disease was diagnosed
in 73%, 67% got percutaneous endoscopic gastrostomy and 36% a Nissen-fundoplication. Neurodevelopmental
data: All children made progress, but on a low level: such as fixing and following with the eyes was seen in 76%,
attempting to grasp objects (76%), moderate head control (73%), social smile (70%), rolling from prone to supine (58%),
and sitting without support (9%). Ten percent lost achieved abilities on follow-up. The presence of prenatal symptoms
did not correlate with outcome.
Conclusion: Phenotype of this genetically homogeneous group of PCH2 children was severe with reduced survival,
but compatible with some developmental progress. Our data support the hypothesis of an early onset degeneration
which thereafter stabilizes.Introduction
Pontocerebellar hypoplasias (PCH) are a group of very
rare heterogeneous conditions characterized by prenatal
development of an abnormally small cerebellum and
ventral pons. The main clinical feature is profound
psychomotor retardation. In many cases, the disease is
fatal early in life. To date, seven types of nonsyndromic
PCH have been defined on the basis of clinical and
genetic criteria [1]. PCH Type 2 (PCH2) is the most
frequently reported - with progressive microcephaly* Correspondence: iciar.sanchez@med.uni-tuebingen.de
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article, unless otherwise stated.from birth combined with extrapyramidal dyskinesia, and,
more rarely, pure spasticity. The inheritance of PCH2
follows an autosomal recessive pattern. Ninety percent
of PCH2 cases carry a missense mutation (p.A307S) in
the TSEN54-gene on chromosome 17, which defines the
PCH2A form (OMIM* 608755). Other PCH2 types
(PCH2B, PCH2C and PCH2D) are caused by mutations in
different genes such as TSEN2, TSEN34 and SEPSECS
respectively.
Although the most frequent form of PCH, PCH2A is a
rare condition. The estimated incidence is lower than
1:200.000. The disorder is mainly described on a
neuropathological, neurostructural (imaging) and genetic
level. Descriptions of clinical features tend to summarized Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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of the disease. To our knowledge, there is no standard-
ized clinical characterization describing developmental
milestones.
However, knowledge of the natural course of the disease
is essential for affected families to adjust life perspectives
and for physicians to improve prospective management.
Also, the natural history of PCH2A could also provide
insight into the impact of the gene defect involved and
its protein product in relation to brain function and
development.
Genes involved in PCH2 are important for protein
synthesis during neuronal development [1]. From a neuro-
pathological point of view, PCH2 has been considered a
neurodegenerative disorder as in addition to hypoplastic
(short cerebellar folia with poor branching) also degenera-
tive changes have been reported [2]. Most degenerative
signs, such as sharply demarcated areas where cerebellar
cortex lost its full thickness are thought to result from
regression at an early stage of development. But neuro-
degenerative changes thought to happen at a later stage
are also reported, such as cystic cerebellar degeneration
and vascular changes limited to the cerebellum (such as
intimal proliferation and splitting of the elastica interna)
found in one patient who died at 22 years [2].
Neurodevelopment in an early onset neurodegenerative
disorder is expected to be considerably limited. Two
hypotheses are conceivable: on the one hand, cognitive
and voluntary motor development are absent. This is
how clinical features in PCH2A are usually referred to
[1]. On the other hand, single case reports of affected
individuals suggest that children may make some neu-
rodevelopmental progress [3]. This would support the
hypothesis of an early onset degeneration which thereafter
stabilizes and thus would be compatible with some devel-
opmental progress.
The aim of this study is to describe the phenotypical
variation and natural course in a genetically homogeneous
group of children with PCH2A, e.g. all carrying the
missense mutation (p.A307S) in the TSEN54-gene.
The idea for this study was suggested to us by the PCH2
parents’ organisation in the German speaking countries.
They believe that a more thorough and standardized
knowledge on their children’s disease course will be
helpful for the management of this rare disorder and
will also help future patients.
Patients and methods
Patients were recruited nationwide from April to November
2012 by contacting the families via the PCH2 support
group in Germany and Switzerland.
Informed consent was given by the parents in all cases.
The study was approved by the ethics committee of the
University of Tübingen (no. 105/2012BO2).Inclusion criteria were:
1. Clinical features: primary developmental disorder
with dyskinetic/spastic movement disorder
2. Neuroradiology: The imaging findings of PCH, eg.
pontocerebellar hypoplasia with pontine and
cerebellar hypoplasia affecting cerebellar
hemispheres with dragonfly like configuration
3. Genetics: homozygous p.A307S mutation in the
TSEN54 gene
If siblings were clinically affected as described above,
they were included on the basis of genetic and imaging
findings in the other sibling.
A standardized questionnaire was established, cover-
ing the essential features of the disease. It included the
following items:
1. Age at diagnosis of PCH2A, age at death
2. Family: number of siblings, number of affected siblings,
number of deceased siblings, consanguinity of parents,
country and region of origin of parents and
grandparents
3. Prenatal data: symptoms which have been reported
to be associated to PCH (retardation of fetal growth,
microcephaly, polyhydramnios or increased fetal
movements)
4. Birth: gestational age, multiple birth, birth weight, birth
length, head circumference, Apgar score (at age 1, 5
and 10 minutes), admission to a hospital after birth
(indication, duration, admission to intensive care unit,
duration of mechanical respiratory support)
5. Symptoms (age at onset, age at cessation).
Symptoms were defined as follows:
a) Neurological symptoms:
i) Choreoathetoid movement disorder:
involuntary, uncontrolled, recurring, and
occasionally stereotyped movements. Chorea
means rapid involuntary, jerky, often
fragmented movements. Athetosis means
slower, constantly changing, writhing, or
contorting movements.
ii) Spastic movement disorder: increased tone,
hyperreflexia and Babinski sign resulting in
abnormal pattern of movement and posture
iii) Non epileptic paroxysmal events/dystonic
attacks: sustained dystonic muscle contractions
with abnormal, twisted, c-shaped body posture
associated to malaise lasting several hours, and
EEG without associated epileptic discharges
iv) Epileptic paroxysmal events:
(1) seizures: description of epileptic seizures
supported by EEG abnormalities
Sánchez-Albisua et al. Orphanet Journal of Rare Diseases 2014, 9:70 Page 3 of 11
http://www.ojrd.com/content/9/1/70(2) Status epilepticus: convulsive seizures
lasting for more than 30 minutesb) Non-neurological symptoms:
i) Feeding difficulties: incoordination of sucking
or swallowing, frequent coughing during meals
or a meal lasting longer than 30 minutes
ii) Excessive vomiting: vomiting or regurgitation
of food once per week or more
iii) Excessive sleepiness: the child has to be woken
up for meals
iv) Recurrent infections: more than 5 episodes of
infection-related fever within 6 months
v) Sleep disorder: difficulty falling asleep
(restlessness or being awake during the night
lasting more than 20 minutes four times a
week or more), or difficulty staying asleep
(waking up more than once a night more than
four times a week).
vi) Apneas: cessation of breathing long enough to
cause cyanosis and/or pallor
6. Psychomotor development:
As PCH2A is associated with profound psychomotor
retardation, we defined very simple abilities following the
concept of developmental milestones [4]:
a) Gross motor function:
i) Head control: ability to hold the head for some
minutes in prone position or while sitting with
support. This was scored as present also if the
head control was briefly interrupted by the typical
choreic movements of PCH2A.
ii) Squirming and rolling
iii) Turning from prone to supine, or vice versa
iv) Crawling on all four
v) Sitting without supportb) Fine motor function:
i) attempting to grasp objects: directed movements
towards an object but without reaching it due to
the underlying choreic movement disorder
ii) grasping objects: if the objects were clearly
reached
iii) holding objects: if the objects were reached
and kept in hand
c) Language development:
i) ability to produce consistently certain sounds
to express approval/disapproval
ii) ability to say "yes" or "no" to express approval/
disapproval
d) Cognitive skills and communication:
i) ability to recognize familiar people, ability to
respond consistently to certain familiar objects
(i.e. a toy, a certain ritual, such as thepreparations - dressing, etc.- before a walk, a
swim or something similar)
ii) laughs when talked to
iii) fixing and/or following an object or person
with the eyes
iv) turning the head towards a sound7. Clinical parameters:
a) Weight, length and head circumference at birth, age
6 weeks, 4 months, 7 months, 1 year, 2 years,
3 years, 4 years, 5 years and current data (evaluated
according to growth charts by Voigt and Schneider
for length [5], weight and head circumference in the
first week of life and the WHO Lenny charts, which
include body mass index (BMI), thereafter [6].
b) Surgeries performed and age at procedure: Nissen
fundoplication, tracheostomy tube placement,
percutaneous endoscopic gastrostomy (PEG)
placement.
In addition to the questionnaire, parents were asked
for consent that available medical records and MRIs were
collected. The questionnaire was sent to the parents and
answered with support from one of the authors (SF) in a
standardized telephone interview, which lasted between
one and two hours. The answers were compared with the
medical reports. In case of contradiction, the item was not
considered for evaluation. If parental and medical data
were consistent, data not explicitly described in the med-
ical records were accepted. All items were answered by
the parents. Movement disorders were derived in most
cases from medical charts. In the few cases, in which no
classification of the movement disorder was available, it
was made by three of the authors (ISA, SF and IKM) on
the basis of the parents’ description.
Prenatal symptomatic and prenatal asymptomatic patients
In the literature [3] prenatal onset characterized by the
symptoms given above is described to be associated with
a more severe disease course (classified as PCH4 and
PCH5). Therefore, we were interested in the disease
course of children with prenatal signs in comparison to
those without.
Statistical analysis
Quantitative data are presented as mean or median
values, standard deviation (SD) and range. Qualitative
data between groups were compared by Fisher’s exact
test. For quantitative data t test was used. Significance
was assumed if p values were <0.05.
Results
Data from 34 patients were collected. One child was
lacking the genetic results and therefore excluded. A
total of 33 patients (17 male; 16 female) with PCH2A,
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All met the clinical criteria and 32 had the typical MRI
findings (one clinically equally affected sibling was not im-
aged). In 31 children, the homozygous p.A307S mutation
in the TSEN54-gene was found (two more children had
clinically equally affected siblings). Four children of our
cohort had been included in the publication by Steinlin
et al. [7].
Seven families had 2 affected children. There were neither
families with more than 2 affected children nor multiple
births. There were no consanguineous parents. The country
of origin of the grandparents - siblings were counted
only once - was known in 101 cases: Germany (n = 78),
Switzerland (n = 7), Poland (n = 10) and Russia (n = 6).Survival
Nine patients (3 girls and 6 boys) had died at the time of
the interview. The mean age at the time of death was
6 years and 7 months (SD: 58 months, range: 7 months –
15 years and 6 months). If considering follow-up until the
age of 10 years, eight out of 15 children (53%) had died
(Figure 1) - three of them before age 6 and five between
age 6 and 10. One child had died beyond the age of 10,
at 15 years and 6 months. Reported causes and circum-
stances of death were: sudden unexpected death at
night (n = 5), multiorgan failure (n = 1), seizure with apnea
(n = 1), pneumonia (n = 1) and hypothermia (n = 1). The
latter case concerned a 15 year old child with progressive
fall in body temperature which could not be stabilized
with medical measures and led to death.
Patients alive at the time of the interview (n = 24) were
on average 7 years and 9 months old (SD: 67 months,
range: 12 months - 19 years and 6 months): two children
were younger than 2 years, eight were between 2 and 5,
eight were between 6 and 9, three were between 10 and
15, and three were between 16 and 20. The male:female
ratio of patients alive was 1:1,18 (11 boys, 13 girls),
respectively.Figure 1 Survival until age 10 years (n=15).Prenatal and neonatal period
Prenatal signs typically associated to PCH were reported
in 10 children: microcephaly was detected in 4 children
by cranial ultrasound at a gestational age between 32
and 35 weeks, in 4 cases there was polyhydramnios, and
a total of 6 mothers perceived shaking or trembling fetal
movements – which were perceived similar to the abnor-
mal movements after birth.
Prenatal cranial ultrasonographic findings
In addition to routine ultrasonography – which was per-
formed in 29 cases - a special ultrasound examination of
brain and cerebellum was performed in 8 pregnancies.
Indication was an affected sibling (n = 4), gestational dia-
betes (n = 1), advanced maternal age (n = 1), oligohydram-
nios (n = 1) and unknown (n = 1). It was unrevealing in 7
cases. A posterior fossa fluid collection was seen in one
case. In another case, a cranial MRI was carried out in the
21st gestational week and was considered normal except
for a cisterna magna size at the upper limit of the normal
range. This has already been reported by Steinlin et al. [7].
Birth and neonatal period
There was one preterm birth in week 36. Umbilical artery
pH was in 3 cases below 7.20 (minimum: 7.12). The lowest
Apgar score was 6 at 5 minutes (n = 1) and 8 at 10 minutes
(n = 1). Birth weight was under the 10th percentile
(2420 g) in one case. A total of 20 children (61%) had
to be treated for one or several reasons at a Children's
Hospital immediately after birth. The average length of
stay in hospital was 15 days. Main reasons for admis-
sion to hospital in the neonatal period were: respira-
tory difficulties and/or apnea (n = 9, 27%), feeding
difficulties (n = 28, 85%, 13 of them requiring a nasogas-
tric tube), jitteriness (n = 21, 64%), abnormal muscle tone
(n = 23, 70%) and excessive sleepiness (n = 19, 58%). Two
newborns (6%) required a short-term respiratory assistance.
In addition to the symptoms described above, seizures
were reported in 2 children and excessive crying in 13.
Anthropometric measurements
All but 6 (82%) were normocephalic at birth, but all
children developed microcephaly during infancy. Four
of the six had been diagnosed with microcephaly already
during pregnancy. In the other two, microcephaly was
evident after birth. Birth weight and birth length were
normal in all at birth. As shown in Figures 2, 3, 4, 5, all
anthropometric measurements fell below – 2SD on
follow up. Especially microcephaly was markedly progres-
sive with increasing age. At birth, it was with a mean value
of −1.24 SD in the lower range of normality and at
age 5 years the mean SD value of head circumference
was −5.58 (range: −2.95 to −8.84), whereas mean length
(−2.14 SD) and mean weight (−2.51 SD) were not as
Figure 2 Evolution of mean length (SD) (n=33).
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mal range again at age 5 years.
Neurological findings
Choreathetoid movements were reported in 29 (88%) pa-
tients. They were noticed either immediately after birth orFigure 3 Evolution of mean weight (SD) (n=33).in the first six months of life (average: 3.8 months, SD 4.2).
In addition to choreathetosis, 18 of these 29 children had
exaggerated tendon reflexes which were in 4 children com-
bined with sustained ankle clonus and a Babinki sign. The
other 4 children exhibited a pure spastic movement dis-
order. Movement disorder persisted in all cases.
Figure 4 Evolution of mean BMI (SD) (n=33).
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- Eleven children presented with paroxysmal, long-lasting,
non-epileptic attacks, which we called "dystonic attacks".
Frequency of dystonic attacks was between twice a week
and twice a year. During the several hours of the attacks,Figure 5 Evolution of mean head circumference (SD) (n=33).children adopted an abnormal, twisted, c-shaped body
posture. Attacks were associated with malaise and often
vomiting.
Mean age of presentation was 15 months (SD: 19 months,
range: 3 months - 6 years) (Figure 6). Dystonic attacks
Figure 6 Onset and duration of dystonic attakcs in 10 children with PCH2. The bar represents the age (in months) of onset of attacks; if the
bar is followed by a line, attacks stopped at that age. One further child is not represented, because age at onset was not known.
Table 1 Effectiveness of antiepileptic drugs in seizure
reduction in 25 children with PCH2A and epilepsy
Antiepileptic drug Number of children
with this medication
Reduction in seizure
frequency (number
of children)
Carbamazepine 3 2
Clobazam 6 1
Lamotrigine 3 1
Levetiracetam 8 2
Oxcarbazepine 4 1
Phenobarbital 15 11
Sultiam 4 2
Topiramate 7 6
Sodium valproate 6 3
Vigabatrin 3 1
Only antiepileptic drugs given in more than 2 cases are considered.
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of age. The patient not included in the figure, because of
unknown age at onset, is currently 19 years old and still
suffers from dystonic attacks. In 8 of the 11 children,
dystonic attacks only ceased with natural, not drug-
induced sleep. Analgesics and L-Dopa were not reported
to show benefit. Medication such as diazepam, phenobar-
bital or chloral hydrate was partially effective in only two
children. In two cases, an improvement of dystonic attacks
occurred in connection with a dose increase of proton
pump inhibitor.
Seizures
Seizures occurred in 27 of 33 children (82%). The 6
children in whom no seizures were reported were below
the age of 28 months. On average, the first seizure oc-
curred at the age of 2 years and 5 months (SD: 28 months,
range: 0 months – 9 years).
Patients had frequent (up to several times a day) and
different seizure types: The most frequently occurring
seizure types were: tonic-clonic (n = 9), atypical absence
(n = 9), myoclonic (n = 6), tonic (n = 4), focalized (n = 3),
atonic (n = 2), associated with apneas (n = 10).
Many families reported febrile seizures occurring. 25
children were put on antiepileptic drugs, 15 of them
combined two or more drugs (Table 1). Seizure freedom
was achieved in only 3 cases. If we consider antiepilepticdrugs given to more than 5 children, a decrease in seiz-
ure frequency in more than half of the patients was
reached with phenobarbital and topiramate. The lowest
effectiveness was obtained by levetiracetam, which showed
a benefit in only 2 out of 8 children.
Characteristic EEG abnormalities were diffuse, abnormal
slow activity and multifocal epileptiform discharges. They
became evident with increasing age. EEGs in the neonatal
period were in nine cases assessed as unremarkable.
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(13 out of 33). Nine children had one episode, 3 had two
and one child had three. The age distribution of the first
episode was heterogeneous. On average, the children
had their first or only status at age 4 years (46.9 months,
SD: 34.6 months, range: 3 months 12 years).
Neurodevelopmental data
Discrepancies between the answers of the questionnaire
and the medical reports were seen in 5 singular answers,
which were discarded. It concerned fixing and/or following
an object or person with the eyes (n = 3), laughing when
talked to (n = 1) and head control (n = 1).
As shown in Figure 7, most children reached a partial
head control, were able to roll and attempted to grasp
objects without reaching them, vocalized to express
approval/disapproval, showed a social smile, recognized
familiar people and had some visual pursuit. Only few of
them were able to get on all fours, sit without support and
say "yes" and "no". Data on language abilities were based
on the parents' answers in the questionnaire and could
not be validated by medical reports. Fixing and following
with the eyes was described in medical records only for
slow moving objects and for short time intervals.
Once an ability was acquired, it was not lost again in
most children. In a few children, some functions were
lost subsequently: rolling from prone to supine in 6 outFigure 7 Neurodevelopmental abilities in 33 patients with PCH2A.of 19 children aged between 2 and 8 years, sitting with-
out support (one out of 3, achieved at age 3 and lost at
age 8,5), attempting to grasp objects (2 out of 25, at age
6.5 and 8), vocalizations (n = 1, at age 9), social smile
(1 out of 24, 4%, at age 13.5), following with the eyes
(1 out of 24, 4%, at age 6).
Language development was either absent (n = 10) or
absolutely rudimentary (n = 19, 56%). In 16 cases, it was
reported that joy and well-being could be distinguished
from malaise. Three children produced more sophisti-
cated vocalizations according to their parents: a child
had different sounds, with which he reacted to different
caregivers or with which he expressed hunger and thirst.
In addition, another child produced recognizable sounds,
accompanied by gestures to express approval or dislike.
Four more children were able to produce meaningful
words such as “yes” and “no”.
Non-neurological symptoms
All patients had feeding problems. Feeding difficulties
started in the first 6 months of life and ceased only in 2
children (6%), who learned to eat small amounts of mushy
food with little bits and pieces of foods. The rest of the
children were able to swallow at best finely pureed foods
(and this with considerable difficulty). A PEG was placed
in 22 children at an average age of 3 years and 8 months
(SD: 3 years and 4 months, range: 6 months - 14 years).
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Onset was in the first months of life. It improved in 11
cases at an average age of 4 years and one month
(6 months- 8 years and 9 months). Frequency of vomiting
was in 6% once a week, in 24% between once a week and
once a day and in 64% more than once a day. Gastro-
esophageal reflux disease was diagnosed in 24 cases. All
but one of the 6 children not diagnosed with gastroesoph-
ageal reflux had a long history of vomiting. 18 patients
were treated with proton pump inhibitors. A Nissen
fundoplication was performed in 12 at an average age
of 4 years and 7 months (SD: 28 months, range:
9 months- 8 years and 9 months).
A total of 17 (52%) patients had recurrent infections, es-
pecially upper respiratory tract infections, bronchitis and/
or pneumonia (including aspiration pneumonia). One child
had, in addition to pneumonias, recurrent urinary tract
infections. Infections led to 2 hospitalizations per year.
- Sleep disorders: A total of 32 out of 33 (96%) patients
exhibited sleep disorders. These started at an average age
of 3.7 months (SD: 6.4 months, range: 0–27 months) and
improved in 9 cases at an average of 5 years (SD: 35 months,
range: 6 months – 12 years). Average time to fall asleep
was 70 minutes (SD: 46 minutes, range: 5 – 180 minutes).
The mean frequency of nocturnal awakening was 3 times
(SD: 1.9 times, range: 0 – 10 times). The only child without
sleep disorder was 2 years and 4 months old.
Apneas occurred in 22 children (67%), especially at
night. Most parents reported a frequency of 2 – 4 apneas
per night. Apneas ceased in 5 cases between the age of
8 months and 16 years (median: 42 months). Tactile stimu-
lation was usually sufficient to terminate an isolated apneic
event. Thirteen children were monitored using a pulse
oximeter, a tracheostomy tube was placed in 5 children at
an average age of 7 years (range: 15 months – 14 years).
Problems in temperature regulation were reported by
many parents, and concerned mainly hyperthermia with-
out evidence of infection (20 children, 60%). Hypothermia
was reported only in the child aged 15 (where it led to
death), and in one more case immediately after birth.
Diagnosis
The mean age at diagnosis depended on the year of birth:
on average, 6 months for children born after 2008 (SD:
5 months, range: 6 days - 14 months), 12 months for chil-
dren born between 2003 and 2008 (SD: 28 months, range:
3 days - 120 months), and 5 years for children born before
2003 (SD: 64 months, range: 15 days - 17 years). In 4
cases, the diagnosis was made after death.
Comparison between prenatal symptomatic and prenatal
asymptomatic patients
Survival rate in the prenatal symptomatic and prenatal
asymptomatic group differed neither at age 1 (8 out of 10vs. 22 out of 22, p = 0.09), nor at age 5 (7 out of 9 vs. 16
out of 17, p = 0.3), nor at age 10 (3 out of 7 vs. 4 out of 8,
p = 1).
The groups did not differ with respect to symptoms in
the neonatal period. There was no difference neither in
the frequency of admission to hospital between prenatal
symptomatic and asymptomatic patients (70% vs. 56%,
p = 0.7), nor in average length of stay in hospital (19 vs.
13 days, p = 0.1) nor concerning need for respiratory
support (n = 1 in both groups).
In the postneonatal period, frequency of dystonic attacks,
seizures, constipation, recurrent infections, sleep disorders
and apneas was similar in both groups. Neurodevelopmen-
tal milestones were achieved by a similar proportion of
children of both groups at a similar age. The only excep-
tion was the ability to recognize familiar objects, which
was more frequent in the prenatal asymptomatic patients
(22 out of 23 [95.7%] vs. 7 out of 10 [70%], p = 0.04).
Discussion
We investigated the natural course in a cohort of 33
children with PCH2A using a standardized questionnaire
and medical records. PCH2 is a very rare disease, less
than 100 families have been reported so far [1,8]. In the
Dutch and German population the carrier frequency of
the responsible mutation is 0.004 [1]. PCH2 is a severe
condition with high mortality in childhood and profound
disability [3]. We wanted to know whether the condition
is characterized by a lack of any neurodevelopmental
progress and increasing burden of multi-morbidity or
whether some developmental milestones can be achieved
despite severe multimorbidity, informations which are
crucial for affected families. Inclusion criteria were clinical
and MRI findings along with a pathogenic mutation. We
restricted our inclusion criteria to homozygosity of the
p.A307S mutation in the TSEN54-gene (also called
“common mutation”, which defines the PCH2A form)
for several reasons: first, it is the most common mutation
and responsible for 90% of PCH2 cases; second, in center-
ing on a homogeneous genotype, a detailed phenotyping
will shed light on the effects of the gene defect involved.
We could characterize PCH2A concerning the disease
course and neurodevelopment with respect to the follow-
ing domains
– Survival and prenatal onset
– Anthropometric measures
– neurological symptoms including paroxysmal events
– developmental progress
– additional morbidity – feeding and sleeping
problems.
Life expectancy was considerably reduced in our cohort.
Most patients did not reach puberty, consistent with what
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prenatal signs such as polyhydramnios, microcephaly and
abnormal fetal movements (shaking, trembling move-
ments) are considered features of the more severe forms
of PCH, PCH4 and PCH5 [1], we compared the course
of children showing these signs to those who did not.
Prenatal signs were found in ten out of the 33 children,
and they did differ from prenatally asymptomatic children
neither concerning survival nor perinatal complications,
postnatal symptoms nor anthropometric measures. Neu-
rodevelopment was also similar in both groups. Thus, at
least in children carrying the mutation (p.A307S) in the
TSEN54-gene, prenatal symptoms do not seem to be
negative predictors of postnatal severity.
Anthropometric measures were mostly within the nor-
mal range at birth. A markedly progressive microcephaly
is known to become more evident with increasing age
[3,7]. We could quantify the microcephaly to fall below
5 SDs whereas both failure to thrive and short stature
were not as severe, falling below 2 SDs.
Neurological symptoms including paroxysmal events
Nearly 90% of patients showed a predominant choreathe-
totic movement disorder present in the first months of
life, only a few had pure spasticity. This is consistent with
the first description by Barth [9].
Seizures were very frequent and heterogeneous, even
in the same patient. EEG abnormalities in all were dif-
fusely abnormal slow rhythms and multifocal epilepti-
form discharges. The risk of status epilepticus was
high. The epilepsy was drug resistant in most cases.
Seizures types and EEG abnormalities have not been
systematically described in previous studies. Only Grosso
et al. described generalized tonic-clonic seizures in a case
report [10]. In the study of Steinlin et al. [7], only half of
PCH2 children (n = 24) were reported with epilepsy,
which could be due to a younger age at assessment (not
reported).
To our knowledge, the symptom "dystonic attacks" has
not been systematically described. Grosso et al. [10] re-
ported on one child with what they called ‘dystonic cri-
ses’ which could correspond to the feature we describe,
as they report repetitive dystonic posturing of one leg in
extension associated with irritability and crying. In our
study, one third showed such attacks, the appearance of
which was uniform: dystonic posturing with a c-shaped
posture for several hours accompanied by malaise and
often vomiting, without associated epileptiform dis-
charges on EEG. Attacks ceased with age in half of the
affected children. They seem difficult to treat as medica-
tion was not reported effective in our cohort. In most
cases, they only ceased with natural, not drug-induced
sleep. The pathomechanism is unknown. Interestingly,
in 2 children they improved after increasing the dose ofa proton pump inhibitor, which might suggest a connec-
tion to gastroesophageal reflux.Developmental progress
PCH2A is associated with profound disability [3,7]. In
our cohort, no patient ever achieved the milestones of
crawling, standing, walking or talking. Visual fixation
was persistently poor. Nevertheless, around two third
of children made some progress, although on a very
low level: they gained partial head control, were able to
roll and attempted to grasp objects without reaching
them, vocalized to express approval/disapproval,
showed a social smile, recognized familiar people and
had some visual pursuit. A few could even sit without
support and get on all fours, in contrast to previous
reports [7]. Some functions such as grasping objects
seemed impaired not only because of the cognitive
impairment, but due to the dyskinetic movement
disorder.
Interestingly, only a few patients lost the functions
they had achieved, although PCH2A has been consid-
ered a neurodegenerative disorder [2]. PCH2A is due to
mutations in three tRNA splicing endonuclease (TSNE)
subunit genes. Intron containing tRNAs require the
TSEN complex for splicing of tRNA, which is an essen-
tial step in protein synthesis [11]. These processes are
important in developing neurons. It has been suggested
that there is a time frame during embryogenesis in
which there is an extra high demand for protein synthe-
sis in neuronal tissue in the early post-migratory stage
which could explain an early degeneration with some
stabilization thereafter [1]. Our results support this hy-
pothesis of an early onset degeneration leading to severe
pontocerebellar maldevelopment and insufficient brain
growth which may, however, stabilize thereafter and is
compatible with some developmental progress. The se-
vere microcephaly during development - which is much
more marked than the deficit of length growth – may
have two explanations: 1) the cerebellum establishes mil-
lions of projections to the telencephalon, especially to
the frontal lobe [12] during fetal and early infantile life.
PCH most certainly disturbs this development. 2) On
the other hand, an ongoing neurodegeneration may also
play a role.Additional morbidity –feeding and sleeping problems
All patients exhibited early abnormalities. Feeding difficul-
ties (sucking or swallowing difficulties, excessive vomiting)
had already been described [3]. They are most likely due
to both bulbar dysfunction and gastroesophageal reflux. In
our cohort, gastroesophageal reflux disease was diagnosed
or could be clinically suspected in almost all children. We
think, it is an important observation, which could
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condition very early.
Sleeping problems have not been previously reported,
but were present in virtually all patients of our cohort.
Both average time to fall asleep and frequency of nocturnal
awakenings were affected.
The frequency of apneas per night was based on the
parents’ reports and might be underdiagnosed, as only
13 out of 22 children in which apneas were described
were monitored using a pulse oximeter. Parents may not
be able to recognize every single apnea during a night.
Actually, apnea might be a common cause of death in
our cohort: the parents reported in 5 cases sudden unex-
pected death and in one case seizures with apnea.
In conclusion, our group of patients with PCH2A -
genetically homogeneous, all carrying the homozygous
missense mutation (p.A307S) in the TSEN54-gene –
showed a severe, but nevertheless variable phenotype.
Survival was reduced and most patients did not reach
puberty. Anthropometric measures, within the normal
range at birth, showed markedly progressive microcephaly
falling below 5 standard deviations from the mean already
in the second year of life, whereas both failure to thrive
and short stature only fell below 2 SDs. Neurological signs
were characterized mainly by choreoathetosis. Epileptic
seizures were prominent and difficult to treat. A feature
described for the first time were dystonic attacks occur-
ring in one third of patients and lasting for several hours
which seemed to be painful; onset was in the first two
years of life and attacks often persisted for years. In
addition, feeding problems requiring PEG and Nissen-
fundoplication, sleep disorders, apneas, and recurrent
infections contributed to severe multi-morbidity. Despite
this, around two third of the patients made some develop-
mental progress in both cognitive and motor domains.
Interestingly, the presence of prenatal symptoms did not
correlate with a poorer prognosis.
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